The oligonucleotide therapeutics market size has the potential to grow by USD 901.18 million during 2020-2024, and the market's growth momentum will accelerate during the forecast period. The increasing incidence of cancer and increased availability of approved drugs are few of the critical oligonucleotide therapeutics market drivers and trends fueling the growth of the market.
This report provides a detailed analysis of the market by application (neurological disorder, cancer, and others), technology (Antisense/RNAi oligonucleotides, and others), and geography (APAC, Europe, MEA, North America, and South America).
An in-depth scenario-based approach was followed in this oligonucleotide therapeutics market research report to identify the direct and indirect impact of COVID-19 on market growth. Buy the full market research report to gain actionable insights on the impact of COVID-19 on oligonucleotide therapeutics market segments.
What was the Oligonucleotide Therapeutics Market Size in 2019?

Browse TOC and LoE with selected illustrations and example pages of Oligonucleotide Therapeutics Market
Request a FREE sample now!
What are the Key Oligonucleotide Therapeutics Market Drivers and Trends?
The growing incidence of cancer that leads to a rise in demand for novel diagnostics will be one of the major factors driving the market growth. Several factors, such as increased pollution and adoption of a sedentary lifestyle, cause diseases such as cancer, CVD, diabetes, and autoimmune diseases. The rate of cancer has increased drastically in the last few years, and the need for novel therapeutics has increased simultaneously. Oligonucleotide therapeutics are gaining traction as it can produce a new class of nucleic acid probes known as aptamers, which are better probes than monoclonal antibodies.
The need for personalized medicines for neurodegenerative disorders, one of the oligonucleotide therapeutics market trends, will also influence the growth of the market in focus. The aged population has an increased risk for degenerated nerves, which deteriorate with time. Alzheimer's disease is one of the most common neurodegenerative disorders. Thus, the growth in aged population results in an increase in the number of individuals with Alzheimer's disease, and limitations in conventional medicines have increased research on alternative techniques such as oligonucleotide therapeutics for Alzheimer's disease. For instance, the anti-tau compound LMTX is considered to have the potential to improve cognitive abilities in individuals with Alzheimer's disease. The administration of this molecule in mice produced a form of the tau protein that acted as a tau protein aggregation inhibitor, thereby delaying the progression of Alzheimer's disease in mice. Such experiments provide useful insights into the viability of oligonucleotide therapies to treat Alzheimer's disease, thus driving the market for oligonucleotide therapeutics. Such factors will drive market growth at a CAGR of over 9%.
Which is the Largest Market Segment Contributing to the Oligonucleotide Therapeutics Market Growth?

Request for a FREE sample and Get more information on the market contribution of various segments
Neurological disorders is the largest application segment in the oligonucleotide therapeutics market. The increase in the elderly population and the R&D investment by several vendors to develop therapeutics for neurological disorders will drive the growth of the market.
Market growth in this segment will be slower than the growth of the market in cancer and others' segment. Request for a FREE SAMPLE to get an accurate prediction of the contribution of all the segments to the growth of the oligonucleotide therapeutics market size.
Which are the Key Markets for Oligonucleotide Therapeutics?

For more insights on the market share of various regions Request for a FREE sample now!
Europe will offer several growth opportunities to market vendors during the forecast period. The increasing approval of products will significantly influence the growth of the oligonucleotide therapeutics market share of this region. 31% of the market's growth will originate from Europe during the forecast period. The UK and Germany are the key markets for oligonucleotide therapeutics in Europe. Market growth in this region will be slower than the growth of the market in APAC.
Who are the Major Oligonucleotide Therapeutics Market Vendors?
The oligonucleotide therapeutics market analysis report provides information on the production, sustainability, and prospects of several leading companies, including:
- Alnylam Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Biogen Inc.
- Dynavax Technologies Corp.
- GlaxoSmithKline Plc
- Ionis Pharmaceuticals Inc.
- Merck & Co., Inc.
- Miragen Therapeutics Inc.
- PCI Biotech Holding ASA
- Sarepta Therapeutics Inc.
The market is fragmented because of the presence of a large number of vendors. This oligonucleotide therapeutics industry analysis report will help clients identify new growth opportunities and design new growth strategies. Also, this report offers a competitive analysis of the players in the antisense oligonucleotides market along with information on the products offered by the companies.

Request for a FREE sample
Key Highlights of the Oligonucleotide Therapeutics Market Report for 2020-2024
- CAGR of the market during the forecast period 2020-2024
- Detailed information on factors that will drive oligonucleotide therapeutics market growth during the next five years
- Precise estimation of the oligonucleotide therapeutics market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the oligonucleotide therapeutics industry across APAC, Europe, MEA, North America, and South America
- A thorough analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of oligonucleotide therapeutics market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Application
- Market segments
- Comparison by Application placement
- Neurological disorders - Market size and forecast 2019-2024
- Cancer - Market size and forecast 2019-2024
- Others - Market size and forecast 2019-2024
- Market opportunity by Application
Market Segmentation by Technology
- Market segments
- Comparison by Technology placement
- Antisense/RNAi oligonucleotides - Market size and forecast 2019-2024
- Others - Market size and forecast 2019-2024
- Market opportunity by Technology
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- APAC - Market size and forecast 2019-2024
- South America - Market size and forecast 2019-2024
- MEA - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
Drivers, Challenges, and Trends
- Market drivers
- Volume driver - Demand led growth
- Volume driver - Supply led growth
- Volume driver - External factors
- Volume driver - Demand shift in adjacent markets
- Price driver - Inflation
- Price driver - Shift from lower to higher priced units
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Alnylam Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Biogen Inc.
- Dynavax Technologies Corp.
- GlaxoSmithKline Plc
- Ionis Pharmaceuticals Inc.
- Merck & Co. Inc.
- Miragen Therapeutics Inc.
- PCI Biotech Holding ASA
- Sarepta Therapeutics Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape